Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 ...
NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing ...
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HITPhase 2 data showed a greater than 25% absolute reduction ...